Emerging drugs to treat alcoholism
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Alcoholism is a widespread disorder with substantial mortality and negative treatment outcomes. To date, few medications have been found to reduce relapse rates or drinking in alcohol-dependent patients. AREAS COVERED IN THIS REVIEW: This review focuses on drugs that have been clinically tested for the treatment of alcohol dependence in clinical trials, pilot trials or which are considered to have a clinical perspective. For this purpose, a detailed Medline search was conducted on this issue. Although the neurochemical basis of alcoholism and the neuronal circuitry mediating its psychotropic effects have been explored in great detail in recent years, few drugs have emerged for the treatment of alcohol dependence, also because pharmaceutical companies have only a limited interest in this area of research. Acamprosate and the opioid antagonist naltrexone have been found to be effective, although data are mixed. A depot formula of naltrexone and the alternate opioid antagonist nalmefene have been studied in clinical trials and will presumably be introduced in the markets soon. Other emerging drugs are topiramate, novel acetaldehyde dehydrogenase (ALDH) inhibitors, baclofen, a combination therapy of gababentin and flumazenil and drugs targeting the cortitropin-releasing factor/neuropeptide Y mediated stress axis. WHAT THE READER WILL GAIN: Insights on the neurochemical basis of alcohol dependence and possible targets of medications. TAKE HOME MESSAGE: Acamprosate, naltrexone and the ALDH inhibitor disulfiram are proven medications for the treatment of alcohol dependence with modest efficacy. Novel alternate medications, a depot formulation of the opioid antagonist naltrexone and another oral opioid antagonist, nalmefene, are available now with good evidence for clinical efficacy. Novel ALDH inhibitors, antiepileptic drugs such as topiramate and drugs targeting the stress axis are currently among the most promising emerging drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Reward-motivated learning: mesolimbic activation precedes memory formation
Adcock, R. A., Thangavel, A., Whitfield-Gabrieli, S., Knutson, B., & Gabrieli, J. D. E. (2006) · Neuron · doi:10.1016/j.neuron.2006.03.036 · Cited by 977
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Edenberg, H. J., Dick, D. M., Xuei, X., Tian, H., Almasy, L., Bauer, L. O., Crowe, R. R., Goate, A., Hesselbrock, V., Jones, K., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/383283 · Cited by 655
Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Ruan, W. J., & Pickering, R. P. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.4.361 · Cited by 644
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption
Spanagel, R., Pendyala, G., Abarca, C., Zghoul, T., Sanchis-Segura, C., Magnone, M. C., Lascorz, J., Depner, M., Holzberg, D., Soyka, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1163 · Cited by 594 · cited 2×
“In a study with Per2Brdm1 mutant mice [24], acamprosate was shown to mediate the dysfunction of the circadian clock gene Per2 and associated alcohol consumption, indicating that acamprosate has a normalizing effect on glutamate transmission.”
BackgroundOslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451 · cited 1×
“While a re-analysis of a data subset from the COMBINE study [66] confirmed this observation, a retrospective analysis of the Affairs Cooperative Study [59] did not find a preferential effect of naltrexone treatment on any of the variants of the OPRM1 gene [67].”
Result
Cited by
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963
Koppaka, V., Thompson, D. C., Chen, Y., Ellermann, M., Nicolaou, K. C., Juvonen, R. O., Petersen, D., Deitrich, R. A., Hurley, T. D., & Vasiliou, V. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005538 · Cited by 557
Burkett, J. P., Spiegel, L. L., Inoue, K., Murphy, A. Z., & Young, L. J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.117 · Cited by 133
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Metadata
- Authors
- Soyka, M., & Rösner, S.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2010-06-19
- Volume
- 15
- Issue
- 4
- Pages
- 695-711
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2084868576
- Cited by
- 40
- References
- 26
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging drugs to treat alcoholism. https://app.cochat.ai/papers/10.1517/14728214.2010.500811
- The paper
- Soyka, M., & Rösner, S. (2010). Emerging drugs to treat alcoholism. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728214.2010.500811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.